Order: Betrixaban 160 mg PO STAT

Available: Refer to the med label below

How many capsules will you administer? (Insert the numerical value only)

A. Respiratory arrest and coma: These are late, life-threatening manifestations of local anesthetic systemic toxicity (LAST) that occur after CNS and cardiovascular collapse. Recognizing early signs is critical to preventing progression to this severe stage.
B. Ventricular arrhythmias and cardiac arrest: These are also late signs of LAST, resulting from the anesthetic’s depressant effects on cardiac conduction. By the time these occur, toxicity is advanced and may require immediate resuscitation measures.
C. Hypotension and tachycardia: Although cardiovascular symptoms may eventually develop, they are typically preceded by neurological signs. Early identification and management of CNS symptoms can often prevent progression to cardiovascular compromise.
D. Tinnitus, metallic taste, and perioral numbness: These are classic early signs of LAST and indicate CNS involvement. They often occur within minutes of administration and should prompt immediate intervention to stop drug absorption and initiate supportive care.

A. Second-generation antihistamines have shorter half-lives and require more frequent dosing compared to first-generation antihistamines: Second-generation antihistamines typically have longer half-lives, allowing once-daily dosing. They are designed for sustained action with improved compliance and fewer side effects.
B. First-generation antihistamines block both histamine and muscarinic receptors, while second-generation antihistamines primarily block histamine receptors: First-generation agents, such as diphenhydramine, cross the blood-brain barrier and exert anticholinergic effects by blocking muscarinic receptors. Second-generation antihistamines are more selective for peripheral H1 receptors, resulting in fewer CNS and anticholinergic side effects.
C. First-generation antihistamines are less likely to cause sedation compared to second-generation antihistamines: First-generation antihistamines are more likely to cause sedation because they easily penetrate the blood-brain barrier and affect central H1 receptors, unlike second-generation agents.
D. Second-generation antihistamines cross the blood-brain barrier, causing significant central nervous system effects: These medications are designed not to cross the blood-brain barrier significantly, which is why they are much less sedating and have minimal CNS effects compared to first-generation antihistamines.